Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants
Polycystic Ovarian Syndrome, Hyperandrogenism, Menstrual Irregularities
About this trial
This is an interventional prevention trial for Polycystic Ovarian Syndrome focused on measuring combined oral contraceptives, drospirenone, cyproterone, hemostasis, antioxidants
Eligibility Criteria
Inclusion Criteria:
- Women aged 18-35 years
- Absence of contraindications for COC use
- Informed voluntary consent for examination
Exclusion Criteria:
- Age younger than 18 and older than 35 years
- Refusal or failure to comply with the study protocol
- Drug or alcohol dependence
- Psychiatric diseases
- Severe somatic and allergic diseases
- Pregnancy
- Malignancies
- Taking drugs that affect haemostasis, including hormonal contraceptives during 6 months before study beginning
- Cases of thrombosis among first-line relatives in family history
- Contraindications to the COC use under Eligibility Criteria of hormonal contraception (WHO, 2012)
Sites / Locations
- Tyumen State Medical AcademyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
No Intervention
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Control group
20 mcg EE/3 mg drospirenone
20 mcg EE/3 mg drospirenone and Selmevit
30 mcg EE/3 mg drospirenone
30 mcg EE/3 mg drospirenone and Selmevit
35 mcg EE/2mg cyproterone
35 mcg EE/2 mg cyproterone and Selmevit
Healthy women that no use combined oral contraceptives
Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit